JP6445423B2 - Ｒｓｖ、ｍｐｖおよびｐｖｍを中和する抗体およびその利用 - Google Patents

Ｒｓｖ、ｍｐｖおよびｐｖｍを中和する抗体およびその利用 Download PDF

Info

Publication number
JP6445423B2
JP6445423B2 JP2015501002A JP2015501002A JP6445423B2 JP 6445423 B2 JP6445423 B2 JP 6445423B2 JP 2015501002 A JP2015501002 A JP 2015501002A JP 2015501002 A JP2015501002 A JP 2015501002A JP 6445423 B2 JP6445423 B2 JP 6445423B2
Authority
JP
Japan
Prior art keywords
antibody
rsv
mpv
antigen
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015501002A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015514068A (ja
JP2015514068A5 (OSRAM
Inventor
コルティ，ダヴィデ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Humabs Biomed SA
Original Assignee
Humabs Biomed SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed SA filed Critical Humabs Biomed SA
Publication of JP2015514068A publication Critical patent/JP2015514068A/ja
Publication of JP2015514068A5 publication Critical patent/JP2015514068A5/ja
Application granted granted Critical
Publication of JP6445423B2 publication Critical patent/JP6445423B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2015501002A 2012-03-20 2013-03-14 Ｒｓｖ、ｍｐｖおよびｐｖｍを中和する抗体およびその利用 Active JP6445423B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261613197P 2012-03-20 2012-03-20
US61/613,197 2012-03-20
US201261655310P 2012-06-04 2012-06-04
US61/655,310 2012-06-04
PCT/IB2013/000627 WO2013140247A1 (en) 2012-03-20 2013-03-14 Antibodies that neutralize rsv, mpv and pvm and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018224174A Division JP6722264B2 (ja) 2012-03-20 2018-11-29 Ｒｓｖ、ｍｐｖおよびｐｖｍを中和する抗体およびその利用

Publications (3)

Publication Number Publication Date
JP2015514068A JP2015514068A (ja) 2015-05-18
JP2015514068A5 JP2015514068A5 (OSRAM) 2018-11-01
JP6445423B2 true JP6445423B2 (ja) 2018-12-26

Family

ID=48471031

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015501002A Active JP6445423B2 (ja) 2012-03-20 2013-03-14 Ｒｓｖ、ｍｐｖおよびｐｖｍを中和する抗体およびその利用
JP2018224174A Expired - Fee Related JP6722264B2 (ja) 2012-03-20 2018-11-29 Ｒｓｖ、ｍｐｖおよびｐｖｍを中和する抗体およびその利用
JP2020106004A Active JP7069251B2 (ja) 2012-03-20 2020-06-19 Ｒｓｖ、ｍｐｖおよびｐｖｍを中和する抗体およびその利用
JP2022076023A Pending JP2022132244A (ja) 2012-03-20 2022-05-02 Ｒｓｖ、ｍｐｖおよびｐｖｍを中和する抗体およびその利用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018224174A Expired - Fee Related JP6722264B2 (ja) 2012-03-20 2018-11-29 Ｒｓｖ、ｍｐｖおよびｐｖｍを中和する抗体およびその利用
JP2020106004A Active JP7069251B2 (ja) 2012-03-20 2020-06-19 Ｒｓｖ、ｍｐｖおよびｐｖｍを中和する抗体およびその利用
JP2022076023A Pending JP2022132244A (ja) 2012-03-20 2022-05-02 Ｒｓｖ、ｍｐｖおよびｐｖｍを中和する抗体およびその利用

Country Status (16)

Country Link
US (4) US9498531B2 (OSRAM)
EP (1) EP2828293B1 (OSRAM)
JP (4) JP6445423B2 (OSRAM)
KR (1) KR102149069B1 (OSRAM)
CN (2) CN104350069B (OSRAM)
AU (1) AU2013237087B2 (OSRAM)
BR (1) BR112014023063A2 (OSRAM)
CA (1) CA2865856C (OSRAM)
DK (1) DK2828293T3 (OSRAM)
EA (1) EA030319B1 (OSRAM)
ES (1) ES2657470T3 (OSRAM)
IL (1) IL234710A (OSRAM)
IN (1) IN2014DN07299A (OSRAM)
NZ (1) NZ630920A (OSRAM)
PL (1) PL2828293T3 (OSRAM)
WO (1) WO2013140247A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2828293T3 (pl) 2012-03-20 2018-03-30 Humabs Biomed S.A. Przeciwciała, które neutralizują RSV, MPV i PVM oraz ich zastosowania
WO2014115893A1 (ja) 2013-01-28 2014-07-31 株式会社イーベック ヒト・メタニューモウイルスに特異的なヒト抗体もしくはその抗原結合性断片
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
WO2020160171A1 (en) * 2019-01-29 2020-08-06 Sanford Burnham Prebys Medical Discovery Institute Topically formulated antibody compositions for reducing pathogen transmission and methods of using same
US20230085439A1 (en) * 2019-05-21 2023-03-16 University Of Georgia Research Foundation, Inc. Antibodies that bind human metapneumovirus fusion protein and their use
TW202246317A (zh) * 2021-02-09 2022-12-01 瑞士商休曼生物醫藥股份公司 針對呼吸道融合病毒及其他副黏液病毒的抗體以及使用其之方法
AU2022227761A1 (en) * 2021-02-26 2023-09-28 Fred Hutchinson Cancer Center Protective antibodies against respiratory viral infections
CN115466326B (zh) * 2021-06-11 2024-06-04 中国科学院微生物研究所 一种呼吸道合胞病毒的人源单克隆抗体及其应用
WO2025015321A1 (en) * 2023-07-13 2025-01-16 Vir Biotechnology, Inc. Broadly neutralizing antibodies against rsv and mpv paramyxoviruses

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
DK1351981T3 (da) 2001-01-19 2012-11-26 Vironovative Bv Et virus, der forårsager luftvejssygdom hos modtagelige pattedyr
KR100708398B1 (ko) 2002-03-22 2007-04-18 (주) 에이프로젠 인간화 항체 및 이의 제조방법
CA2494485A1 (en) 2002-07-25 2004-02-05 Medimmune, Inc. Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
WO2004092207A2 (en) * 2003-04-16 2004-10-28 Algonomics N.V. Respiratory syncytial virus (rsv) peptides
EP1473037A1 (en) 2003-05-02 2004-11-03 Vironovative B.V. Treatment of hPMV infections with Ribavirin
JP4976376B2 (ja) * 2005-04-08 2012-07-18 メディミューン，エルエルシー 哺乳動物メタニューモウイルスに対する抗体
EP1997830A1 (en) * 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
EP2350128B1 (en) 2008-10-22 2014-10-01 Institute for Research in Biomedicine Methods for producing antibodies from plasma cells
AU2010264686A1 (en) * 2009-06-24 2012-01-19 Glaxosmithkline Biologicals S.A. Vaccine
JP5762408B2 (ja) * 2009-08-13 2015-08-12 クルセル ホランド ベー ヴェー ヒト呼吸器合胞体ウイルス（ｒｓｖ）に対する抗体および使用方法
TWI539963B (zh) * 2010-07-09 2016-07-01 庫賽爾荷蘭公司 抗－人類呼吸道融合性病毒（ｒｓｖ）抗體及其使用方法
PL2828293T3 (pl) * 2012-03-20 2018-03-30 Humabs Biomed S.A. Przeciwciała, które neutralizują RSV, MPV i PVM oraz ich zastosowania

Also Published As

Publication number Publication date
ES2657470T3 (es) 2018-03-05
US20210115114A1 (en) 2021-04-22
JP2015514068A (ja) 2015-05-18
US20140037648A1 (en) 2014-02-06
EP2828293B1 (en) 2017-10-25
US20170121393A1 (en) 2017-05-04
EA201491724A1 (ru) 2015-01-30
EP2828293A1 (en) 2015-01-28
CA2865856C (en) 2023-03-14
CN104350069B (zh) 2017-12-01
WO2013140247A1 (en) 2013-09-26
IL234710A (en) 2016-12-29
JP7069251B2 (ja) 2022-05-17
BR112014023063A2 (pt) 2017-07-18
JP6722264B2 (ja) 2020-07-15
CN104350069A (zh) 2015-02-11
JP2022132244A (ja) 2022-09-07
IN2014DN07299A (OSRAM) 2015-04-24
CN107880121B (zh) 2022-02-18
US10072071B2 (en) 2018-09-11
NZ630920A (en) 2017-01-27
US9498531B2 (en) 2016-11-22
KR102149069B1 (ko) 2020-08-28
CN107880121A (zh) 2018-04-06
KR20140135259A (ko) 2014-11-25
EA030319B1 (ru) 2018-07-31
HK1206367A1 (en) 2016-01-08
US20190153073A1 (en) 2019-05-23
JP2020182464A (ja) 2020-11-12
AU2013237087A1 (en) 2014-09-18
AU2013237087B2 (en) 2017-07-20
PL2828293T3 (pl) 2018-03-30
US11421020B2 (en) 2022-08-23
CA2865856A1 (en) 2013-09-26
JP2019076091A (ja) 2019-05-23
DK2828293T3 (en) 2018-01-08

Similar Documents

Publication Publication Date Title
JP7069251B2 (ja) Ｒｓｖ、ｍｐｖおよびｐｖｍを中和する抗体およびその利用
AU2009275226B2 (en) Neutralizing anti-influenza a virus antibodies and uses thereof
US11370829B2 (en) Antibodies that potently neutralize RSV and uses thereof
EA039682B1 (ru) Антитела, нейтрализующие rsv, mpv и pvm, и их применения
HK1206367B (en) Antibodies that neutralize rsv, mpv and pvm and uses thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160302

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170516

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20170809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180417

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180717

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20180918

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181030

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181129

R150 Certificate of patent or registration of utility model

Ref document number: 6445423

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250